Cancer Gene Therapy Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Cancer Gene Therapy Market by Type( (Gene Induced Immunotherapy (Tumour Antigen Gene Delivery, Cytokine Gene Delivery), Oncolytic Virotherapy (Adenoviruses, Adeno Associated Virus, Lentiviruses, Alpha Virus, Retrovirus, Herpes Simplex Virus, Vaccinia virus, Simian Virus ) ,Gene Transfer/ Gene Replacement, Electroporation, Magnetofection, Naked / Plasmid Vectors, Gene Gun, Sonoporation)), Therapy (Retroviral Therapy, Adenoviral Therapy), End-User (Hospitals, Oncology institutes, Biotechnological companies, Clinical Research Labs), and by Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Cancer gene therapy market size was valued at USD 629 million in the year 2020 and is anticipated to reach 3351.79 million at a CAGR of 27% by 2027 during the forecast period 2021-2027. Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells. In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.

Cancer gene therapy market report gives comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report on cancer gene therapy market gives historical, current, and future market sizes (US$ Mn) on the basis of type, therapy, end-user, and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in cancer gene therapy


Cancer Gene Therapy Market

MARKET SUMMARY
-
27% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 27%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Cancer Gene Therapy Market Analysis

  • Global cancer gene therapy market is highly fragmented with small biotech firms holding a chunk of the overall industry share. Major industry participants adopting various strategies to retaining their market positions such as the development of advanced technologies, maintaining a strong intellectual property, strategic collaborations, and joint ventures adopted by in the global cancer gene therapy.
  • As per WHO, cancer incidence is projected to rise by 50% to reach 15 Mn by the end of this decade. This alarming increase in the number of patients and side effects associated with various chemotherapy drugs necessitates this as a potential treatment approach addressing the growing global burden of the cancers. Small biotech firms dominate the global cancer gene therapy market than the bigger players.
  • The players are constantly engaged in R&D in order to develop novel methods to treat various life-threatening diseases. Increased in the adoption of emerging genomic technologies such as Next Generation Sequencing (NGS) and high-density microarray coupled with favorable government initiatives will fuel global cancer gene therapy market.
  • For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance.
Market Leaders
  • Urigen Pharmaceuticals Inc. (U.S)
  • GenVec.Inc (U.S)
  • Oxford BioMedica (U.K)
  •  Vical (U.S)
  • ANI Pharmaceuticals, Inc. (U.S)
  • and Genzyme Corporation (U.S)
  • Novartis AG (Switzerland)
  • Cell Medica (U.K.)
Cancer Gene Therapy Market

Drivers and Restraints

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.


Cancer Gene Therapy Market Regional Analysis

North America dominates the market

Geographically, the cancer gene therapy is segmented into North America, Europe, Latin America, Asia- Pacific and the Middle East and Africa. North America leads the global cancer gene therapy market owing to the large pool of aging population and advancements in technology high investments in R & D activities along with the government support will boost industry demand. The U.K. market is anticipated to grow rapidly over the forecast period due to the rising occurrence of cancer along with the increase in acceptance of gene technology. Asia-Pacific is expected to witness high growth in cancer gene therapy market, due to increase in government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for cancer gene therapy market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Cancer Gene Therapy Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Urigen Pharmaceuticals Inc. (U.S)
  • GenVec.Inc (U.S)
  • Oxford BioMedica (U.K)
  •  Vical (U.S)
  • ANI Pharmaceuticals, Inc. (U.S)
  • and Genzyme Corporation (U.S)
  • Novartis AG (Switzerland)
  • Cell Medica (U.K.)

Description

Cancer gene therapy market size was valued at USD 629 million in the year 2020 and is anticipated to reach 3351.79 million at a CAGR of 27% by 2027 during the forecast period 2021-2027. Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells. In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.

Cancer gene therapy market report gives comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report on cancer gene therapy market gives historical, current, and future market sizes (US$ Mn) on the basis of type, therapy, end-user, and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in cancer gene therapy

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX